VOLITIONRX LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.87 USD | -4.78% |
|
+45.00% | +21.34% |
| 04-26 | VolitionRx Limited Announces Board Changes | CI |
| 04-23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
| Sales 2024 * | 3.63M 289M | Sales 2025 * | 16.48M 1.31B | Capitalization | 75.02M 5.97B |
|---|---|---|---|---|---|
| Net income 2024 * | -36M -2.87B | Net income 2025 * | -32M -2.55B | EV / Sales 2024 * | 18.2 x |
| Net cash position 2024 * | 8.9M 708M | Net Debt 2025 * | 18.4M 1.46B | EV / Sales 2025 * | 5.67 x |
| P/E ratio 2024 * |
-2.25
x | P/E ratio 2025 * |
-2.83
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
More press releases
| 1 day | -4.78% | ||
| 1 week | +45.00% | ||
| Current month | +14.93% | ||
| 1 month | +12.39% | ||
| 3 months | -10.31% | ||
| 6 months | +8.61% | ||
| Current year | +21.34% |
1 week
0.61
1.02
1 month
0.571.02
Current year
0.571.23
1 year
0.552.10
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 05/10/11 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 31/01/21 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 31/01/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 05/10/11 |
Martin Faulkes
CHM | Chairman | 80 | 05/10/11 |
Guy Innes
BRD | Director/Board Member | 67 | 05/10/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.87 | -4.78% | 68 684 |
| 26/04/24 | 0.9137 | +2.65% | 210,159 |
| 25/04/24 | 0.8902 | +11.27% | 489,819 |
| 24/04/24 | 0.8 | -5.88% | 354,848 |
| 23/04/24 | 0.85 | +41.67% | 3,440,054 |
Delayed Quote Nyse, April 29, 2024 at 06:51 pm
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9137
USD
Average target price
3.725
USD
Spread / Average Target
+307.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.34% | 75.02M | |
| -19.64% | 10.82B | |
| +47.91% | 3.25B | |
| -32.87% | 2.11B | |
| -14.15% | 2.08B | |
| -25.41% | 1.48B | |
| +18.78% | 1.02B | |
| -2.62% | 733M | |
| -31.12% | 391M | |
| -43.78% | 383M |
- Stock Market
- Equities
- VNRX Stock
